

Erratum

Clinical Trial Highlights – Infusion Therapies

Neha Prakash MD

Parkinson's Disease and Movement Disorders Center, University of Connecticut Health Center, Farmington, CT, USA

Kevin McFarthing PhD

Parkinson's advocate, Innovation Fixer Ltd, Oxford, UK To whom correspondence should be addressed at kevinDOTmcfarthingATinnovationfixerDOTcom

Tanya Simuni MD

Parkinson's Disease and Movement Disorders Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

[Journal of Parkinson's Disease 10(1), 2020, 5–17, DOI 10.3233/JPD-199005]
<https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd199005>

On page 6, line 4, it should say (76%), not (75%).

On page 6, line 5, the following text needs to be deleted:

“However, recent data from the GREENFIELD study reports only 16% device related AE [5].”

On page 6, in the References, the following reference should not have been included:

[5] L. Lopiano, N. Modugno, P. Marano, M. Sensi, G. Meco, P. Solla, G. Gusmaroli, F. Tamma, F. Mancini, R. Quatrone, R. Zangaglia, A. Bentivoglio, R. Eleopra, G. Gualberti, G. Melzi, A. Antonini, Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study, *J. Neurol.* 266 (2019) 2164–2176. doi:10.1007/s00415-019-09337-6.